GlobalData on MSN

Quest Diagnostics’ Haystack MRD test secures NYSDOH approval

The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Quest Diagnostics® (NYSE: DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program ...